Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
“In contrast, branded specialty products represent more than 50% of our clients’ total drug spend and are entirely ignored by the FTC.” Express Scripts, meanwhile, declared in a statement th ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
Dealbreaker on MSN13d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...
The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback